

aripiprazole (Abilify) 5mg tablets

(No. 187/05)

Bristol-Myers Squibb

Product Update

10 June 2005

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Aripiprazole tablets 5mg (Abilify®) are accepted for restricted use in NHS Scotland for the treatment of schizophrenia. Where aripiprazole is an appropriate antipsychotic, this new dosage is restricted to patients who may benefit from a dose reduction to 5mg daily, taking account of SMC advice issued in August 2004. This 5mg tablet is the same price as the 10mg and 15mg tablets.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 13 April 2005.

**Chairman
Scottish Medicines Consortium**